An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations - Full Text View

Purpose

The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.

The primary purpose of this study was to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbored EGFR activating mutations, and had developed resistance to EGFR TKI.

Condition	Intervention	Phase
Advanced Non Small Cell Lung Cancer (NSCLC)	Drug: AUY922 Drug: Docetaxel Drug: Pemetrexed	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: lung cancer

Drug Information available for: Docetaxel Pemetrexed Pemetrexed disodium

Genetic and Rare Diseases Information Center resources: Lung Adenocarcinoma

U.S. FDA Resources

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:

Progression Free Survival (PFS) [ Time Frame: 16 months ]
Compared PFS between the treatment of AUY922 to comparators Pemetrexed or Docetaxel. Progression-free survival (PFS) based on local investigator assessment per RECIST 1.1 was the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient had not had an event, progression-free survival is censored at the date of last adequate tumor assessment. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Secondary Outcome Measures:

Overall Response Rate (ORR) [ Time Frame: 16 months ]
ORR was to be compared between treatment arms. The ORR was to be based on local investigator assessment per Response Evaluation Criteria In Solid Tumors Criteria 1.1 (RECIST 1.1). Per this criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.This outcome measure was originally planned to be analyzed up to 24 months. The DMC recommendation at the IA was to stop the study for futility. As a result, collection of all the efficacy assessments was stopped at that time.
Overall Survival (OS) [ Time Frame: from randomization until death up to death ]
OS is defined as the time from the date of randomization to date of death due to any cause. If a death has not been observed by the date of analysis cutoff, then OS was to be censored at the last known date patient was alive.
Disease Control Rate (DCR) [ Time Frame: baseline, until disease progression up to 24 months ]
Duration of DCR will be compared between treatment arms. The duration of DCR will be based on local investigator assessment per RECIST 1.1
Time to Response (TRR) [ Time Frame: baseline, until disease progression up to 24 months ]
TTR was to compare between treatment arms. The TTR was to be based on local investigator assessment per RECIST 1.1
Duration of Response (DOR) [ Time Frame: baseline, until disease progression up to 24 months ]
The DOR will be compared between treatment arms. The DOR will be based on local investigator assessment per RECIST 1.1
Rate of Adverse Events (AEs) [ Time Frame: baseline, until disease progression up to 24 months ]
To evaluate safety and tolerability of AUY922 compared to chemotherapy agents pemetrexed or docetaxel.
Change in Laboratory Paramenters [ Time Frame: baseline, until disease progression up to 24 months ]
Changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), Dose interruptions, reductions and dose intensity.
Time to Progression (TTP) [ Time Frame: baseline, until disease progression up to 24 months ]
TTP will be compared between treatment arms. The TTP will be based on local investigator assessment per RECIST 1.1


Enrollment:	52
Study Start Date:	November 2012
Study Completion Date:	November 2015
Primary Completion Date:	November 2015 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: AUY922 arm Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm. AUY922 was to be administered weekly.	Drug: AUY922 AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
Active Comparator: chemotherapy arm Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm. Pemetrexed or docetaxel was to be was to be given once every three weeks.	Drug: Docetaxel Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity Other Name: TAXOTERE Drug: Pemetrexed Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity Other Name: ALIMTA

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.
Patients must have EGFR gene mutation in their tumors. This can be source - documented by one of the following:

• Provide a pathology report that indicates the patient's tumor had EGFR activating mutation in the past.

Or:

• Perform testing (local or central) in an archival tumor or a fresh baseline biopsy tumor tissue to show the presence of EGFR activating mutation.
Patients must have documented clinical benefit (CR, PR, or patients with SD for 6 months or greater) on prior EGFR TKI (e.g. erlotinib or gefitinib) followed by documented progression according to RECIST.
Patients must have received prior platinum containing treatment.
WHO performance status of 0-1

Exclusion Criteria:

Patients who have received more than two prior lines of antineoplastic therapy for advanced disease. Chemotherapy administered as neoadjuvant or adjuvant treatment more than six months prior to study enrollment is not considered a prior line of therapy for purposes of this study.
Evidence of spinal cord compression or current evidence of CNS metastases. Screening CT/MRI of the brain is mandatory. Note: Patients who have been treated for CNS metastases by radiation or gamma knife surgery, who been stable for at least 2 months and have discontinued high dose corticosteroids will be eligible for protocol participation
Prior treatment with an HSP90 inhibitor

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01646125

Show 27 Study Locations

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators


Study Director:	Novartis Pharmaceuticals	Novartis Pharmaceuticals

More Information


Responsible Party:	Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT01646125 History of Changes
Other Study ID Numbers:	CAUY922A2207 2012-001050-25 ( EudraCT Number )
Study First Received:	June 26, 2012
Results First Received:	November 3, 2016
Last Updated:	January 23, 2017

Keywords provided by Novartis ( Novartis Pharmaceuticals ):


Non-small cell lung carcinoma (NSCLC) treatment of lung cancer after first metastasis lung cancer lung adenocarcinoma Squamous cell lung carcinoma Large-cell lung carcinoma Non small cell lung carcinoma Non small cell lung cancer Non-small cell lung cancer	NSCLC Large cell lung carcinoma Large cell lung cancer HSP90 AUY922 Pemetrexed Docetaxel EGFR TKI EGFR mutations

Additional relevant MeSH terms:


Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms	Docetaxel Pemetrexed Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on June 23, 2017